Literature DB >> 7634649

Congenital pseudarthrosis of the tibia. Long-term followup of 29 cases treated by microvascular bone transfer.

A Gilbert1, R Brockman.   

Abstract

The authors show that vascularized fibular transplantation is the safest technique to treat congenital pseudarthrosis of the tibia. Results of transplantation in 29 patients reveal that the rate and speed of healing were superior to those of any other published method, and the final outcome at maturity was generally acceptable. In addition, the technique allows secondary lengthening procedures to be done. Various factors, such as age at first fracture, age at operation, gender, and type of fixation, did not appear to influence the outcome significantly.

Entities:  

Mesh:

Year:  1995        PMID: 7634649

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  21 in total

1.  Periosteal grafting for congenital pseudarthrosis of the tibia: a preliminary report.

Authors:  Ahmed M Thabet; Dror Paley; Mehmet Kocaoglu; Levent Eralp; John E Herzenberg; Omer Naci Ergin
Journal:  Clin Orthop Relat Res       Date:  2008-10-25       Impact factor: 4.176

Review 2.  Free vascularised fibular grafts in orthopaedics.

Authors:  Marko Bumbasirevic; Milan Stevanovic; Vesna Bumbasirevic; Aleksandar Lesic; Henry D E Atkinson
Journal:  Int Orthop       Date:  2014-02-22       Impact factor: 3.075

3.  Vascularised fibular graft for the treatment of congenital pseudarthrosis of the tibia: long-term complications in the donor leg.

Authors:  Raquel B Iamaguchi; Patricia M M B Fucs; Antonio Carlos da Costa; Ivan Chakkour
Journal:  Int Orthop       Date:  2010-08-01       Impact factor: 3.075

4.  Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1.

Authors:  David A Stevenson; David H Viskochil; John C Carey; Xiaoming Sheng; Mary Murray; Laurie Moyer-Mileur; Judd Shelton; William L Roberts; Ashley M Bunker; Heather Hanson; Stephanie Bauer; Jacques L D'Astous
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

5.  Progressive valgus deformity of the donor-site ankle after extraperiosteal harvesting the fibular shaft in children. Treatment with osteotomy and synostosis at one session.

Authors:  Fientje J C Van der Veen; Simon D Strackee; Philip P Besselaar
Journal:  J Orthop       Date:  2014-07-19

6.  Masquelet's procedure and bone morphogenetic protein in congenital pseudarthrosis of the tibia in children: a case series and meta-analysis.

Authors:  Bruno Dohin; Remi Kohler
Journal:  J Child Orthop       Date:  2012-07-21       Impact factor: 1.548

7.  Induced membrane technique for the treatment of congenital pseudarthrosis of the tibia: preliminary results of five cases.

Authors:  Stéphanie Pannier; Zagorka Pejin; Caroline Dana; Alain Charles Masquelet; Christophe Glorion
Journal:  J Child Orthop       Date:  2013-10-08       Impact factor: 1.548

8.  Health-related quality of life measures in genetic disorders: an outcome variable for consideration in clinical trials.

Authors:  David A Stevenson; John C Carey
Journal:  Am J Med Genet C Semin Med Genet       Date:  2009-08-15       Impact factor: 3.908

9.  Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.

Authors:  Steven D Rhodes; Xiaohua Wu; Yongzheng He; Shi Chen; Hao Yang; Karl W Staser; Jiapeng Wang; Ping Zhang; Chang Jiang; Hiroki Yokota; Ruizhi Dong; Xianghong Peng; Xianlin Yang; Sreemala Murthy; Mohamad Azhar; Khalid S Mohammad; Mingjiang Xu; Theresa A Guise; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2013-12       Impact factor: 6.741

10.  Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.

Authors:  Richa Sharma; Xiaohua Wu; Steven D Rhodes; Shi Chen; Yongzheng He; Jin Yuan; Jiliang Li; Xianlin Yang; Xiaohong Li; Li Jiang; Edward T Kim; David A Stevenson; David Viskochil; Mingjiang Xu; Feng-Chun Yang
Journal:  Hum Mol Genet       Date:  2013-07-17       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.